Skip to main content
Journal for Immunotherapy of Cancer logoLink to Journal for Immunotherapy of Cancer
. 2024 Oct 15;12(10):e009474corr1. doi: 10.1136/jitc-2024-009474corr1

Correction: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

PMCID: PMC11481152  PMID: 39414326

Davar D, Cavalcante L, Lakhani N, et al. Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). J ImmunoTherapy Cancer 2024;12:e009474. doi: 10.1136/jitc-2024–0 09 474

In the original article, panel B of Figure 1 was a duplicate of panel A:

graphic file with name jitc-12-10-g001.jpg

The correct panel has now been added to the figure:

graphic file with name jitc-12-10-g002.jpg


Articles from Journal for Immunotherapy of Cancer are provided here courtesy of BMJ Publishing Group

RESOURCES